{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:04:32Z","timestamp":1789621472652,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032702","name":"Genmab","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clml.2026.02.006","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:23:24Z","timestamp":1771547004000},"page":"317-327.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6"],"prefix":"10.1016","volume":"26","author":[{"given":"David","family":"Andorsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelba Torres","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2622-0330","authenticated-orcid":false,"given":"Rakhee","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Vargas","family":"Madueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Ibrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9859-151X","authenticated-orcid":false,"given":"Seema","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitul","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Erika","family":"Haydu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Lash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Fesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5731-8226","authenticated-orcid":false,"given":"Suchitra","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojo","family":"Osei-Bonsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Doerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian W.","family":"Eskelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7169-9275","authenticated-orcid":false,"given":"Alexander P.","family":"Boardman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Boccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-6337","authenticated-orcid":false,"given":"Christina Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5611-6115","authenticated-orcid":false,"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2026.02.006_bib0001","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2026.02.006_bib0002","unstructured":"SEER Cancer Stat Facts: Diffuse Large B-Cell Lymphoma. National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html (accessed March 9, 2026)."},{"issue":"1","key":"10.1016\/j.clml.2026.02.006_bib0003","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-025-01702-5","article-title":"Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: recent advances and emerging therapies","volume":"18","author":"Bock","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"23","key":"10.1016\/j.clml.2026.02.006_bib0004","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2026.02.006_bib0005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1053\/j.seminhematol.2023.12.001","article-title":"Second-line treatment of diffuse large B-cell lymphoma: evolution of options","volume":"60","author":"Fabbri","year":"2023","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2026.02.006_bib0006","unstructured":"Epkinly [package insert]. Plainsboro, NJ: Genmab; 2025."},{"key":"10.1016\/j.clml.2026.02.006_bib0007","unstructured":"Columvi [package insert]. San Francisco, CA: Genentech; 2025."},{"issue":"2","key":"10.1016\/j.clml.2026.02.006_bib0008","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"10.1016\/j.clml.2026.02.006_bib0009","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2026.02.006_bib0010","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2026.02.006_bib0011","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1111\/cas.15996","article-title":"Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed\/refractory diffuse large B-cell lymphoma","volume":"114","author":"Izutsu","year":"2023","journal-title":"Cancer Sci"},{"issue":"8","key":"10.1016\/j.clml.2026.02.006_bib0012","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.02.006_bib0013","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2024-198714","article-title":"3-Year update from the Epcore NHL-1 trial: epcoritamab leads to deep and durable responses in relapsed or refractory large B-cell lymphoma","volume":"144","author":"Vose","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.02.006_bib0014","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1200\/JCO.2024.42.16_suppl.7029","article-title":"Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): results from phase 2 EPCORE NHL-6","volume":"42","author":"Andorsky","year":"2024","journal-title":"J Clin Oncol"},{"issue":"S3","key":"10.1016\/j.clml.2026.02.006_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70096_625","article-title":"Outpatient administration of Epcoritamab monotherapy for relapsed\/refractory diffuse large B-cell lymphoma: update from EPCORE NHL-6","volume":"43","author":"Vaidya","year":"2025","journal-title":"Hematol Oncol"},{"issue":"27","key":"10.1016\/j.clml.2026.02.006_bib0016","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.02.006_bib0017","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.clml.2026.02.006_bib0018","doi-asserted-by":"crossref","first-page":"pkae093","DOI":"10.1093\/jncics\/pkae093","article-title":"The intersection of travel burdens and financial hardship in cancer care: a scoping review","volume":"8","author":"Planey","year":"2024","journal-title":"JNCI Cancer Spectrum"},{"issue":"4","key":"10.1016\/j.clml.2026.02.006_bib0019","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/ejh.14444","article-title":"European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions","volume":"115","author":"Lund","year":"2025","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2026.02.006_bib0020","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1200\/OP-24-00921","article-title":"Impatient for outpatient: operationalizing bispecific antibodies for multiple myeloma in the ambulatory setting","volume":"21","author":"Olivieri","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"S3","key":"10.1016\/j.clml.2026.02.006_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70094_198","article-title":"CD3xCD20 Bispecific epcoritamab induces antitumor activity and favorable T-cell dynamics over time with prolonged therapy","volume":"43","author":"Takacs","year":"2025","journal-title":"Hematol Oncol"}],"updated-by":[{"DOI":"10.1016\/j.clml.2026.08.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000}}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:51:02Z","timestamp":1786477862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502600042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S215226502600042X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.02.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}